Product
Netarsudil/Latanoprost Ophthalmic Solution
1 clinical trial
2 indications
Indication
GlaucomaIndication
ocular hypertensionClinical trial
A Phase II, Prospective, Two-Stage, Double-Masked, Randomized, Multi-Center, Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-17043 and PG043 (AR-17043/Latanoprost) Ophthalmic Solutions in Subjects With Elevated Intraocular PressureStatus: Not yet recruiting, Estimated PCD: 2025-11-01